Results 291 to 300 of about 119,702 (338)

A Cell Protective Mechanism in a Murine Model of Parkinson's Disease

, 2003
Emin Öztaş, Turgut Topal
openalex  

Upper Gastrointestinal Mucosal Damage and Subsequent Risk of Parkinson Disease.

JAMA Netw Open
Chang JJ, Kulkarni S, Pasricha TS.
europepmc   +1 more source

An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.

JAMA Neurol
Shanbhag NM, Padmanabhan JL, Zhang Z, Harel BT, Jia H, Kangarloo T, Yin W, Dowling AV, Laurenza A, Khudyakov P, Galinsky K, Latzman RD, Simuni T, Weintraub D, Horak FB, Lustig C, Maruff P, Simen AA.   +17 more
europepmc   +1 more source

Effectiveness of Technological Interventions for Older Adults With Parkinson Disease: Systematic Review.

JMIR Serious Games
Bevilacqua R, Benadduci M, Barbarossa F, Amabili G, Di Donna V, Martella C, Pelliccioni G, Riccardi GR, Maranesi E.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Parkinson's disease

Neurologic Clinics, 2001
A number of changes have occurred in the management of Parkinson's disease in recent years, with the development of new therapeutic strategies based upon advances in pharmacotherapy and interventional procedures. The treatment of patients with Parkinson's disease is considered here with these advances in mind.
A E, Constantino, L S, Honig
openaire   +5 more sources

Parkinson's Disease and Parkinsonism

The American Journal of Medicine, 2019
Parkinson's disease is a progressive neurodegenerative disease characterized by tremor and bradykinesia and is a common neurologic ailment. Male sex and advancing age are independent risk factors and, as the population ages, is taking an increasing toll on productivity and medical resources.
openaire   +2 more sources

Genetics of Parkinson’s disease and parkinsonism

Expert Review of Neurotherapeutics, 2007
The past 10 years has seen a shift in our etiological concepts of Parkinson's disease, moving from a nearly exclusively environmentally mediated disease towards a complex disorder with important genetic contributors. The identification of responsible mutations in certain genes, particularly alpha-synuclein, Parkin, PINK1, DJ-1 and LRRK2, has increased ...
David J Nicholl, Michael R. Douglas, Alistair Lewthwaite   +2 more
openaire   +3 more sources

Parkinson's disease.

Clinical evidence, 2002
Around 1% of adults have Parkinson's disease, with a median time of 9 years between diagnosis and death.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments in people with early-stage Parkinson's disease?
Carl E, Clarke, A Peter, Moore
openaire   +7 more sources